Filspari (Travere) and now Novartis’ Fabhalta and Venrafia provide physicians more options than ever before.EXTON, PA, May 08, 2025 (GLOBE NEWSWIRE) -- With multiple targeted therapies now available ...

As a personal wellbeing specialist, I’ve had the privilege of speaking at various health and wellness events, including one ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Good day, ...

The association between diabetes and periodontitis is bidirectional, meaning that diabetes may worsen periodontitis (chronic ...

With this approval approximately 45 people[i] living with cystic fibrosis, many with a rare mutation, will be newly eligible for a medicine that ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

the early detection of CKD is key to preserving kidney function and avoiding disease complications. Managing diabetes is key to preventing CKD and diabetic nephropathy. The primary aim is to manage ...

Shares of ZyVersa Therapeutics surged Wednesday, drawing heavy attention from retail investors after the company unveiled new ...

The Trade-Adverse Trade Adviser: Once sidelined, President Trump’s counselor Peter Navarro has returned to Washington and ...

This exciting Research Topic is the second volume of the Research Topic "Diabetic Kidney Disease: Routes to drug development, pharmacology and underlying molecular mechanisms." Please see the first ...

Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.06 per share for the first quarter of 2025, missing ...